Using CT scans to predict who benefits from immunotherapy for lung cancer
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11304550
This project uses advanced computer analysis of CT scans to find patterns that show which people with non-small cell lung cancer may benefit from anti‑PD‑1/PD‑L1 immunotherapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11304550 on ClinicalTrials.gov |
What this research studies
From my point of view as a patient, the team is applying new computer‑vision radiomics techniques to routine CT scans to look for imaging features linked to treatment success. They will compare these imaging patterns to real patient outcomes after receiving immune checkpoint inhibitors and work to distinguish true responses from pseudo‑progression that can look like tumor growth. The approach focuses on non‑invasive imaging rather than relying only on tissue biomarkers, and it uses both existing scans and follow‑up imaging to train and test the algorithms. If the methods work, they could be used alongside clinical information to guide treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates are people with non‑small cell lung cancer who are being considered for or already receiving anti‑PD‑1/PD‑L1 immunotherapy and who have CT imaging and medical records available.
Not a fit: People with other cancer types, those without accessible CT scans or treatment records, or patients not treated with immune checkpoint inhibitors are unlikely to directly benefit from this work.
Why it matters
Potential benefit: If successful, this could help doctors predict who will benefit from immunotherapy earlier and avoid ineffective and costly treatments.
How similar studies have performed: Some retrospective radiomics studies have suggested imaging can predict immunotherapy response, but these methods remain experimental and need prospective validation.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MADABHUSHI, ANANT — EMORY UNIVERSITY
- Study coordinator: MADABHUSHI, ANANT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.